Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

Delayed Quote. Delayed  - 08/23 10:00:31 pm
59.86 USD   +1.01%
08/22 ALLIED MINDS : Given New Debt, Raises Funds For Drug Development
08/21 BRISTOL MYERS S : Fukoku Mutual Life Insurance Co Lowers stake in Br..
08/11DJBusiness Watch -- WSJ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Allied Minds : Given New Debt, Raises Funds For Drug Development

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2016 | 10:59am CEST

LONDON (Alliance News) - Allied Minds PLC Monday said it has secured USD20.0 million of new debt to back its work in the US whilst its drug discovery subsidiary has raised an additional USD15.0 million to help support its main project focused on treating fibrotic and autoimmune diseases.

Allied Minds is a US-based investment firm focused on forming, funding, managing and building start-ups based on early-stage technology. The FTSE 250-listed constituent said the new one-year revolving debt facility has been provided by Silicon Valley Bank and is secured against "certain assets".

"We are pleased to have Silicon Valley Bank's support as we continue to build and develop our portfolio and look forward to what we anticipate will be a long-term relationship with Silicon Valley Bank. The facility further diversifies our capital structure and is a powerful endorsement of the group's growth and development prospects," said Chief Executive Chris Silva.

Separately, the company said Allied-Bristol Life Sciences II LLC, part of a joint venture between Allied Minds and Bristol-Myers Squibb Co, has raised USD15.0 million of new equity from investors.

That has been raised after the main joint venture company, Allied-Bristol Life Sciences LLC, said it had successfully completed the drug candidate feasibility programme at ABLS II for novel small molecule therapeutics for the treatment of fibrotic and autoimmune diseases back in May.

Allied Bristol Life Sciences Capital LLC, which includes Allied Minds, Woodford Investment Management and Invesco Asset Management among its investors, contributed USD12.0 million of the total equity raised by ABLS II, with the other USD3.0 million coming from Bristol-Myers Squibb Co.

Allied Bristol Life Sciences Capital, in turn, raised USD12.0 million in equity in order to make its contribution to the fundraising by ABLS II. Allied Minds contributed some funds to that raising, with Woodford contributing USD6.0 million and Invesco USD3.0 million.

The work will be used to further develop the lead optimisation programme, which, if successful, will allow Bristol Myers Squibb Co to purchase Allied Minds' interest in ABLS II at a pre-determined multiple of invested capital.

As previously announced, Allied-Bristol Life Sciences Capital will fund 80% of the next phase of development with Bristol-Myers Squibb Co funding the other 20%.

Allied Minds said its economic interest in ABLS II now stands at 35.95%, which is held through an 80% interest in the joint venture Allied-Bristol Life Sciences LLC and the 30.25% interest held in Allied-Bristol Life Sciences Capital.

Allied Minds shares were trading down 0.3% to 380.82 pence per share on Monday morning.

Copyright 2016 Alliance News Limited. All Rights Reserved.  , source Alliance News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB CO
08/22 ALLIED MINDS : Given New Debt, Raises Funds For Drug Development
08/21 BRISTOL MYERS SQUIBB : Fukoku Mutual Life Insurance Co Lowers stake in Bristol-M..
08/18 BRISTOL MYERS SQUIBB : Study Results from Bristol-Myers Squibb Provide New Insig..
08/18 EIGER BIOPHARMACEUTICALS : Reports Second Quarter 2016 Financial Results
08/18 BRISTOL MYERS SQUIBB : Announces Top-Line Results from CheckMate -026, a Phase 3..
08/18 BRISTOL MYERS SQUIBB : New Glutamic Acid Study Findings Have Been Reported by In..
08/11 BRISTOL MYERS SQUIBB : Studies from Bristol-Myers Squibb Have Provided New Data ..
08/11 BRISTOL MYERS SQUIBB : Study Data from Bristol-Myers Squibb Update Understanding..
08/11 BRISTOL MYERS SQUIBB : An Application for the Trademark "AZENMI" Has Been Filed ..
08/11 BRISTOL MYERS SQUIBB : Patent Issued for Methods for the Preparation of HIV Atta..
More news
Sector news : Pharmaceuticals - NEC
08:20a ASTRAZENECA : to sell antibiotics business to Pfizer
08/23DJU.S. Lawmakers Plan Hearing Over Wave of Agriculture Mergers
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJNew CFO Tops Off Shake-Up At Valeant -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/23 Game Plan For The Week - Cramer's Mad Money (8/22/16)
08/22 Is The Sky Falling Only On Gilead?
08/19 Play Oncology To Play M&A In Big Pharma?
08/19 Profit From Bristol-Myers' Drug Failure And Increased Volatility
08/17 Slimmed-Down Big Pharma Starts Growing Again
Advertisement
Financials ($)
Sales 2016 18 890 M
EBIT 2016 4 944 M
Net income 2016 4 379 M
Debt 2016 1 249 M
Yield 2016 2,59%
P/E ratio 2016 23,15
P/E ratio 2017 19,99
EV / Sales 2016 5,36x
EV / Sales 2017 4,87x
Capitalization 100 018 M
More Financials
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 68,8 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-12.98%100 018
JOHNSON & JOHNSON16.28%326 773
ROCHE HOLDING LTD.-12.26%219 257
NOVARTIS AG-9.97%214 603
PFIZER INC.8.71%212 844
MERCK & CO., INC.20.37%175 812
More Results